Bepreve

Bepreve

Generic: bepotastine besilate 1.5%

Bepreve
DOSAGE 1 gtt BID
GENERIC bepotastine besilate 1.5%
SIZE 5mL, 10mL
INDICATIONS BEPREVEĀ® (bepotastine besilate ophthalmic solution) 1.5% is a histamine H1 receptor antagonist indicated for the treatment of itching associated with signs and symptoms of allergic conjunctivitis.
MECHANISM OF ACTION Combo Mast Cell Stabilizer / Anti H1
MICROBIOLOGY Nedocromil sodium inhibits the release of mediators from cells involved in hypersensitivity reactions. Decreased chemotaxis and decreased activation of eosinophils have also been demonstrated. Also inhibits histamine release from a population of mast cells having been defined as belonging to the mucosal sub type and inhibits beta-glucuronidase release from macrophages.
CONTRAINDICATIONS & WARNINGS BEPREVE is contraindicated in patients with a history of hypersensitivity reactions to bepotastine or any of the other ingredients
PEDIATRIC USE Safety and efficacy of BEPREVE (bepotastine besilate ophthalmic solution) 1.5% have not been established in pediatric patients under 2 years of age.
Efficacy in pediatric patients under 10 years of age was extrapolated from clinical trials conducted in pediatric patients greater than 10 years of age and from adults.
PREGNANCY Category C: There are no available human data for the use of BEPREVE during pregnancy to inform any drug-associated risks .Oral administration of bepotastine besilate to pregnant rats or rabbits during organogenesis or during the pre/postnatal period did not produce adverse embryofetal or offspring effects at clinically relevant systemic exposures. Maternal toxicity was observed in the rabbits at the lowest dose administered
NOTE BAK .005%. Remove contact lenses prior 10mins prior to instillation of BEPREVE.